Subcutaneous Daratumumab Formulation Reduces Treatment Time and Premedication Requirements in Multiple Myeloma
核心洞察
The subcutaneous formulation of daratumumab with hyaluronidase-fihj (Darzalex Faspro) allows multiple myeloma (搜索) patients to complete treatment visits in under one hour compared to 3-4 hours with intravenous administration.
After the first treatment cycle, patients receiving subcutaneous daratumumab can forgo premedication and observation requirements that are necessary with each intravenous infusion cycle.
The subcutaneous formulation maintains a similar adverse event profile to intravenous daratumumab while providing improved convenience through a 15 ml injection administered slowly in the abdomen.
The subcutaneous formulation of daratumumab with hyaluronidase-fihj (Darzalex Faspro) is transforming treatment efficiency for multiple myeloma (搜索) patients by dramatically reducing clinic time and premedication requirements compared to the intravenous formulation, according to nursing experts from leading cancer centers.
Significant Reduction in Treatment Time
Heather Wenberg, BSN, RN, OCN, regional director of nursing at the American Oncology Network (搜索), explained that patients receiving subcutaneous daratumumab "can be in and out of the clinic within 1 hour at the most with labs and their injection." This represents a substantial improvement over intravenous administration, where patients typically require a 3-hour infusion plus additional time for premedications and monitoring.
"As far as decreasing chair time, if patients were getting the IV version [of daratumumab], they would have an IV in their arm, [receiving] premeds all the time, and they would have a 3-hour infusion each time," Wenberg noted. "By having the subcutaneous option, they get their labs, then they are clear. We do our double checks, they get their injection."
Streamlined Premedication Protocol
The subcutaneous formulation allows for a more patient-friendly premedication approach. While intravenous daratumumab requires premedications at each treatment cycle, the subcutaneous version only requires intensive premedication and monitoring for the first cycle.
For the initial treatment, patients receive 50 mg of IV Benadryl, 20 mg of IV dexamethasone, and oral acetaminophen, followed by approximately 60 minutes of waiting time before the subcutaneous injection. Healthcare providers then monitor patients for about 2 hours after the first administration. "Once they're doing fine, we omit that observation," Wenberg explained.
Gina Fries, PA-C, a physician assistant at the University of Rochester Medical Center, detailed the standard premedication protocol: "We do this standard Tylenol [acetaminophen], Benadryl [diphenhydramine], dexamethasone combination that is for multiple drugs, including daratumumab infusions and subcutaneous injections. For the very first 4 doses of subcutaneous daratumumab, we give montelukast beforehand."
Administration and Safety Profile
The subcutaneous formulation combines daratumumab with hyaluronidase in a 15 ml injection administered slowly in the abdomen. Stephanie Mompoint, APRN, a research advanced practice nurse at the University of Miami Health System, explained that "these 2 components really help for better absorption of the daratumumab in the fatty tissue."
The safety profile remains consistent with the intravenous formulation. "The AEs are expected to be the same [as the IV formulation]. That's why it's important to premedicate patients, just like you would have with IV daratumumab," Mompoint emphasized.
Clinical Implementation and Patient Benefits
The subcutaneous formulation has become the preferred option at many cancer centers. "Subcutaneous administration is our formulary for American Oncology Network (搜索), so that's our go-to for all of our patients," Wenberg stated.
The treatment must still be administered in clinical settings under professional supervision. "Daratumumab must be given in the infusion unit; it's not something that a patient can take at home on their own. The patient will come in and have the injection administered by a nurse," Mompoint clarified.
Healthcare providers report high patient satisfaction with the subcutaneous option. "Most patients do very well with it, and they like the subcutaneous administration of daratumumab," Wenberg observed, noting that the reduced time commitment and simplified premedication schedule contribute to improved treatment experience without compromising therapeutic outcomes.